Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2. It promotes activation of CASP3, and thereby apoptosis. It undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis under stress conditions.

The Apoptosis regulator BAX – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Apoptosis regulator BAX, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Apoptosis regulator BAX and features dormant and discontinued projects.

Key Therapy Areas in the Apoptosis Regulator BAX Pipeline Drugs Market

The key therapy areas in the Apoptosis Regulator BAX pipeline drugs market are Oncology, Cardiovascular, Central nervous System, and Ophthalmology.

Apoptosis Regulator BAX Pipeline Drugs Market, by Therapy Areas

Apoptosis Regulator BAX Pipeline Drugs Market, by Therapy Areas

For more target insights, download a free report sample

Key MoA in the Apoptosis Regulator BAX Pipeline Drugs Market

The key mechanisms of action in the Apoptosis Regulator BAX Pipeline Drugs Market are Apoptosis Regulator BAX Activator, and Apoptosis Regulator BAX Inhibitor.

Apoptosis Regulator BAX Pipeline Drugs Market, by MoA

Apoptosis Regulator BAX Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Apoptosis Regulator BAX Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Apoptosis Regulator BAX pipeline drugs market are Oral, Intratumor, Intravenous, and Intravenous Bolus.

Apoptosis Regulator BAX Pipeline Drugs Market Analysis, by RoA

Apoptosis Regulator BAX Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Apoptosis Regulator BAX Pipeline Drugs Market

The key molecule types in the Apoptosis Regulator BAX pipeline drugs market are Small Molecule, and Synthetic Peptide.

Apoptosis Regulator BAX Pipeline Drugs Market, by Molecule Type

Apoptosis Regulator BAX Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Apoptosis Regulator BAX Pipeline Drugs Market

The major companies in the Apoptosis Regulator BAX pipeline drugs market are BAKX Therapeutics Inc, Genervon Biopharmaceuticals LLC, Lytix Biopharma AS, and PHD Biosciences.

Apoptosis Regulator BAX Pipeline Drugs Market, by Major Companies

Apoptosis Regulator BAX Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Apoptosis Regulator BAX Pipeline Drugs Market Overview

Key Targets Oncology, Cardiovascular, Central nervous System, and Ophthalmology
Key Mechanisms of action Apoptosis Regulator BAX Activator, and Apoptosis Regulator BAX Inhibitor
Key Routes of Administration Oral, Intratumor, Intravenous, and Intravenous Bolus
Key molecule types Small Molecule, and Synthetic Peptide
Major companies BAKX Therapeutics Inc, Genervon Biopharmaceuticals LLC, Lytix Biopharma AS, and PHD Biosciences

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Apoptosis Regulator BAX
  • The pipeline guide reviews pipeline therapeutics for Apoptosis Regulator BAX by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Apoptosis Regulator BAX therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Apoptosis Regulator BAX therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Apoptosis Regulator BAX

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Apoptosis Regulator BAX
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Apoptosis Regulator BAX pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

BAKX Therapeutics Inc
Genervon Biopharmaceuticals LLC
Lytix Biopharma AS
PHD Biosciences

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Overview

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Companies Involved in Therapeutics Development

BAKX Therapeutics Inc

Genervon Biopharmaceuticals LLC

Lytix Biopharma AS

PHD Biosciences

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Drug Profiles

BKX-001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CYD-211 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GM-6 – Drug Profile

Product Description

Mechanism Of Action

History of Events

LTX-401 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate Apoptosis Regulator BAX for Lung Cancer – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit BAX for Myocardial Infarction – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit BAX for Ophthalmology – Drug Profile

Product Description

Mechanism Of Action

SMBA-1 – Drug Profile

Product Description

Mechanism Of Action

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Dormant Products

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) – Product Development Milestones

Featured News & Press Releases

Feb 15, 2022: Lytix Biopharma granted 3 MNOK from Oslo Regional Research Fund

Feb 26, 2018: Genervon Presents Innovative CNS Drug Candidate at 2018 BIO CEO & Investor Conference

Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS

Apr 06, 2017: Lytix Biopharma presents poster on LTX-401 at AACR in Washington April 2017

Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published

Jan 10, 2017: Genervon Releases ALS, PD and AD Disease­ Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm

Dec 27, 2016: ALS and Alzheimer’s disease bioinformatics reports confirm GM6’s role as regulator of disease-relevant pathways

Sep 21, 2016: Lytix Biopharma develops second generation oncolytic molecules for deep seated tumors

Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS

May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604

May 03, 2016: GM604 to Be Granted “Orphan Drug” Status in Europe

Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression

Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease

Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA

Jan 08, 2015: Genervon Announces ALS Compassionate Use Results

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by BAKX Therapeutics Inc, 2022

Pipeline by Genervon Biopharmaceuticals LLC, 2022

Pipeline by Lytix Biopharma AS, 2022

Pipeline by PHD Biosciences, 2022

Dormant Projects, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.